A perspective on surrogate endpoints in controlled clinical trials

Statistical Methods in Medical Research

Volumn 13, Issue 3, 2004, Pages 177-206

  Molenberghs, Geert ^a   Burzykowski, Tomasz ^a   Alonso, Ariel ^a   Buyse, Marc ^b  

^a HASSELT UNIVERSITY   (Belgium)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DOXORUBICIN; FLUOROURACIL; FLUTAMIDE; LIAROZOLE; PLATINUM; PROSTATE SPECIFIC ANTIGEN; RISPERIDONE;

ADVANCED CANCER; ANALYTICAL ERROR; CALCULATION; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; EVIDENCE BASED MEDICINE; HUMAN; LINEAR SYSTEM; MEDICAL DECISION MAKING; NORMAL DISTRIBUTION; OUTCOMES RESEARCH; PROSTATE CANCER; REGRESSION ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCHIZOPHRENIA; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 2942525565     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280204sm362ra     Document Type: Review

References (52)

1. Prentice RL. Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 1989; 8: 431-40.
2. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125: 605-13.
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction. New England Journal of Medicine 1989; 321: 406-12.
4. DeGruttola V, Tu XM. Modelling progression of CD-4 lymphocyte count and its relationship to survival time. Biometrics 1995; 50: 1003-14.
5. Lagakos SW, Hoth DF. Surrogate markers in AIDS: Where are we? Where are we going? Annals of Internal Medicine 1992; 116: 599-601.
6. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001; 69: 89-95.
7. Ferentz AE. Integrating pharmacogenomics into drug development. Pharmacogenomics 2002; 3: 453-67.
8. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annual Review of Pharmacololgy and Toxicology 2001; 41: 347-66.
9. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Statistics in Medicine 2003; 22: 2239-56.
10. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nature Reviews Cancer 2002; 2: 19-27.
11. International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Last accessed 5th April 2004. (http://www.ich.org/pdfICH/e9.pdf), Federal Register 1998, 63, No. 179, 49583.
12. Buyse M, Molenberghs G. Criteria for the validation of surrogate end-points in randomized experiments. Biometrics 1998; 54: 1014-29.
13. Molenberghs G, Geys H, Buyse M. Evaluation of surrogate end-points in randomized experiments with mixed discrete and continuous outcomes. Statistics in Medicine 2001; 20: 3023-38.
14. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-68.
15. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. Applied Statistics 2001; 50: 405-22.
16. Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M. Validation of surrogate endpoints in multiple randomized clinical trials with discrete outcomes. Biometrical Journal 2002; 44: 921-35.
17. Alonso A, Geys H, Molenberghs G, Vangeneugden T. Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology. Journal of Biopharmaceutical Statistics 2002; 12: 161-78.
18. Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M, Vangeneugden T and Bijnens L. Validation of a longitudinally measured surrogate marker for a time-to-event endpoint. Journal of Applied Statistics 2002; 30: 235-47.
19. Buyse M, Vangeneugden T, Bijnens L, Geys H, Renard D, Burzykowski T, Molenberghs G. Validation of Biomarkers as Surrogates for Clinical Endpoints. In Bloom JC and Dean RA, eds Biomarkers in Clinical Drug Development. Marcel Dekker: New York, 2003.
20. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P, for the Meta-Analysis Group In Cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000; 356: 373-78.
21. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. The validation of surrogate endpoints using data from randomized clinical trials: a case study in advanced colorectal cancer. Journal of the Royal Statistical Society, Series A 2004; 167: 103-24.
22. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16: 1515-27.
23. Gail MH, Pfeiffer R, van Houwelingen HC, Carroll RJ. On meta-analytic assessment of surrogate outcomes. Biostatistics 2000; 1: 231-46.
24. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11: 167-78.
25. Choi S, Lagakos S, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Annals of Internal Medicine 1993; 118: 674-80.
26. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1997; 16: 1515-27.
27. Flandre P, Saidi Y. Letter to the editor: estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1999; 18: 107-15.
28. Begg C, Leung D. On the use of surrogate endpoints in randomized trials. Journal of the Royal Statistal Society Series A 2000; 163: 26-27.
29. Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Controlled Clinical Trials 2002; 23: 607-25.
30. Cook RD, Weisberg S. Residuals and influence in regression. London: Chapman & Hall, 1982.
31. Chatterjee S, Hadi AS. Sensitivity analysis in linear regression. New York: John Wiley & Sons, 1988.
32. Clayton DG. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 1978; 65: 141-51.
33. Hougaard P. Survival models for heterogeneous populations derived from stable distributions. Biometrika 1986; 73, 387-96.
34. Genest C, McKay J. The joy of copulas: bivariate distributions with uniform marginals. American Statistician 1986; 40, 280-83.
35. Shih JH, Louis, TA. Inferences on association parameter in copula models for bivariate survival data. Biometrics 1995; 51, 1384-99.
36. Geys H, Regan M, Catalano P, Molenberghs G. Two latent variable risk assessment approaches for combined continuous and discrete outcomes from developmental toxicity data. Journal of Agricultural, Biological, and Environmental Statistics 2001; 6, 340-55.
37. Dale JR. Global cross ratio models for bivariate, discrete, ordered responses. Biometrics 1986; 42: 909-17.
38. Galecki A. General class of covariance structures for two or more repeated factors in longitudinal data analysis. Communications in Statistics: Theory and Methods 1994; 23: 3105-19.
39. Kent, J. Information gain and a general measure of correlation. Biometrika 1983, 70, 163-73.
40. Debruyne FJM, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, de Porre P for the Liarozole Study Group. Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology 1998; 52: 72-81.
41. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. Journal of Clinical Oncology 1995; 13: 2944-53.
42. Smith DC, Dunn RL, Strawderman MS, et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. Journal of Clinical Oncology 1998; 16: 1835-43.
43. Kelly WK, Scher HI, Mazumdar M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology 1993; 11: 607-15.
44. Scher HI, Kelly WK, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. Journal of the National Cancer Institute 1999; 91: 244-51.
45. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Fidd WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. Journal of Clinical Oncology 1999; 17: 3461-67.
46. Buyse M, Piedbois P. On the relationship between response to treatment and survival. Statistics in Medicine 1996; 15: 2797-812.
47. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. Journal of Clinical Oncology 1983; 1: 710-19.
48. DeGruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modelling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. Journal of Acquired Immune Deficiency Syndromes 1993; 6: 359-65.
49. Diagnostic and therapeutic technology assessment (DATTA). Surrogate markers of progressive HIV disease. Journal of the American Medical Association 1992; 267: 2948-52.
50. Ellenberg SS. Surrogate endpoints in clinical trials: getting closer to identifying markers for survival in AIDS. British Medical Journal 1991; 302: 63-64.
51. Machado SG, Gail MH, Ellenberg SS. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. Journal of Acquired Immune Deficiency Syndromes 1990; 3: 1065-73.
52. Tibaldi FS, Abrahantes JC, Molenberghs G, Renard D, Burzykowski T, Buyse M, Parmar M, Stijnen T, Wolfinger R. Simplified hierarchical linear models for the evaluation of surrogate endpoints. Journal of Statistical Computation and Simulation 2003; 73: 643-58.